Hepatitis C: Management of side effects in the era of direct-acting antivirals

Current Gastroenterology Reports

Volumn 15, Issue 1, 2013, Pages

  Gaetano, John N ^a   Reau, Nancy ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Direct acting antivirals; Hepatitis C; Side effects; Triple therapy

Indexed keywords

ALFUZOSIN; ALPRAZOLAM; ANTIHISTAMINIC AGENT; ANTIVIRUS AGENT; BOCEPREVIR; CARBAMAZEPINE; COLCHICINE; CORTICOSTEROID; EFAVIRENZ; EPLERENONE; ERGOT DERIVATIVE; ERYTHROPOIETIN; HEMOGLOBIN; MEVINOLIN; MIDAZOLAM; NEVIRAPINE; PEGINTERFERON ALPHA; PHENYTOIN; RIBAVIRIN; SIMVASTATIN; SULFONYLUREA; TELAPREVIR; TRIAZOLAM;

ADVERSE OUTCOME; ANEMIA; ANXIETY; ARTICLE; DEPRESSION; DERMATITIS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG WITHDRAWAL; ECZEMA; FATIGUE; HEPATITIS C; HUMAN; INSOMNIA; IRRITABILITY; MYALGIA; NEUTROPENIA; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PRURITUS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE; VIRUS RESISTANCE; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG INTERACTION; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; REVIEW;

ANTIVIRAL AGENTS; DRUG ERUPTIONS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HEPATITIS C, CHRONIC; HUMANS;

EID: 84871408060     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-012-0305-1     Document Type: Article

References (21)

1. Manns MP, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-65. (Pubitemid 32913521)
2. Fried MW, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-82.
3. PEGASYS (peginterferon alfa-2a) Package Insert, H.-L.R. Inc., Nutley, NJ 07110.
4. PEG-Intron (peginterferon alfa-2b) Package Insert. a.s.o.M.C. Schering Corporation, Inc., Whitehouse Station, NJ 08889, USA.
5. Roomer R, et al. Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. J Hepatol. 2010;53(3):455-9.
6. Cacoub P, Bourlière M, Lübbe J, Dupin N, Buggisch P, Dusheiko G, Hézode C, Picard O, Pujol R, Segaert S, Thio B, Roujeau JC. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol. 2012;56(2):455-63.
7. Lotrich F. Management of psychiatric disease in hepatitis C treatment candidates. Curr Hepat Rep. 2010;9:113-8.
8. Udina M, Castellví P, Moreno-España J, et al. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry. 2012;73(8):1128-38.
9. •• Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, SPRINT-,1 Investigators, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376:705-16. The SPRINT-1 trial is the major phase 2 trial evaluating the effectiveness and safety of triple therapy with boceprevir in treatment-naïve patients with chronic hepatitis C. This study proved the large-scale effectiveness and relative safety of triple therapy, as compared with standard PEG-IFN/RBV dual therapy.
10. •• Poordad F, McCone JJ, Bacon BR, Bruno S, Manns MP, Sulkowski MS, SPRINT-2 Investigators, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-206. The SPRINT-2 trial succeeds the SPRINT-1 trial to further evaluate treatment regimens for naïve CHC patients without cirrhosis. The SPRINT-2 data allowed for FDA support of response-guided therapy with the use of boceprevir.
11. •• Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, ADVANCE Study Team, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-16. This study identified 12 weeks of triple therapy with telaprevir followed by dual therapy in a response-guided fashion as an optimal regimen over standard dual therapy. In addition, it showed that the development of an extended RVR was the strongest predictor of SVR.
12. • Poordad F, Bronowicki JP, Gordon SC, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. SPRINT-2 and RESPOND-2 Investigators. Gastroenterology. 2012;143(3):608-18. Although anemia is recognized as a significant adverse effect of HCV therapy, it is also strongly associated with treatment efficacy. This was first recognized with dual PEG/RBV therapy and continues to hold true for triple therapy, as made evident by this study.
13. • Sulkowski MS, Poordad F, Manns MS, Bronowicki JP, Reddy KR, Harrison SA, et al. Anemia during treatment with peginterferon alfa-2b/ribavirin with or without boceprevir is associated with higher SVR rates: analysis of previously untreated and previous-treatment-failure patients. J Hepatol. 2011;54(1):S195-6. This study allows for the recommendation to be made to treat anemia with ribavirin dose reduction and was a subanalysis from the SPRINT-2 data.
14. •• Bacon BR, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207-17. Boceprevir-based triple therapy resulted in significantly higher rates of SVR in previously treated patients with chronic HCV genotype 1 infection, as compared with dual therapy.
15. Sulkowski MS, Reddy R, Afdhal NH, Di Bisceglie AM, Zeuzem S, Poordad F, et al. Anemia had no effect on efficacy outcomes in treatment-naive patients who received telaprevir-based regimen in the ADVANCE and ILLUMINATE phase 3 studies. J Hepatol. 2011;54 suppl 1:S195.
16. FDA. Transcript for the meeting of the Antiviral Drugs Advisory Committee. April 27, 2011 Accessed 8/31/12 at: http://www.fda.gov/downloads/ advisorycommittees/committeesmeetingmaterials/drugs/ antiviraldrugsadvisorycommittee/UCM257464.pdf
17. Hezodé C, Dorival C, Zoulim F, et al. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non responders: first results of the French early access program (ANRS CO20-CUPIC). Barcelona, Spain: Program and abstracts of the 47th Annual Meeting of the European Association for the Study of the Liver; 2012.
18. FDA. Transcript for the meeting of the Antiviral Drugs Advisory Committee. April 28, 2011 Accessed 8/31/12 at: http://www.fda.gov/downloads/ advisorycommittees/committeesmeetingmaterials/drugs/ antiviraldrugsadvisorycommittee/UCM257465.pdf
19. Liapakis A, Jacobson I. Telaprevir user's guide. Clin Liver Dis. 2011;15(3):555-71.
20. Incivek (telaprevir) Package insert. Cambridge, MA: Vertex Pharmaceuticals Inc; 2012.
21. Victrelis (boceprevir) Package Insert. Whitehouse Station, NJ: Shering Corp; 2012.